Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
24.49
-0.80 (-3.16%)
Nov 20, 2024, 4:00 PM EST - Market closed
Beam Therapeutics Employees
Beam Therapeutics had 436 employees as of December 31, 2023. The number of employees decreased by 71 or -14.00% compared to the previous year.
Employees
436
Change (1Y)
-71
Growth (1Y)
-14.00%
Revenue / Employee
$801,933
Profits / Employee
-$329,337
Market Cap
1.95B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
National HealthCare | 13,123 |
Patterson Companies | 7,600 |
Evotec SE | 5,061 |
Tandem Diabetes Care | 2,400 |
NeoGenomics | 2,100 |
GeneDx Holdings | 1,000 |
Supernus Pharmaceuticals | 652 |
MannKind | 414 |
BEAM News
- 8 days ago - Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference - GlobeNewsWire
- 13 days ago - Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch - Seeking Alpha
- 15 days ago - Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs - GlobeNewsWire
- 23 days ago - Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting - GlobeNewsWire
- 3 months ago - Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results - GlobeNewsWire
- 4 months ago - Beam Therapeutics Announces Transition of Chief Financial Officer - GlobeNewsWire
- 5 months ago - Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) - GlobeNewsWire